BMEA Nilai Total Aset Perusahaan Biomea Fusion Inc

BMEA (Biomea) - tandha merek perusahaan

Biomea Fusion, Inc. (BMEA) management is focused on creating breakthrough therapies for oncology and diabetes by correcting beta-cell function. The business relies on accessible covalent molecule technology, which guarantees massive operating leverage upon commercialization. This market valuation chart for the company on the GURU.Markets platform shows total assets at 55.02, highlighting hidden pricing power due to the high value of the oral medications under development.

BMEA (Biomea Fusion, Inc.) riwayat Total Aset Perusahaan saka 04.07.2022 nganti 30.10.2026

Rincian analitis lan laporan data perusahaan Biomea (BMEA)

- nilai pasar lan prakiraan target analis:
Rega saham biomeafusion.com|BMEA - Bagan rega target
- data kapitalisasi pasar:
Biji pasar Biomea Fusion Corp|BMEA - Nilai Perusahaan
- statistik nilai buku emiten:
Nilai Akuntansi Saham Biomea Fusion|BMEA - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku biomeafusion.com|BMEA - Aset Agregat Perusahaan
- indikator beban utang lan likuiditas:
Rasio Kabeh Utang marang Dana Pribadi Biomea Fusion, Inc.|BMEA - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Biomea Fusion Corp|BMEA - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Biomea Fusion Corp|BMEA - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Biomea Fusion|Indikator likuiditas cepet biomeafusion.com
- indikator pendapatan resik lan kelipatan nilai:
BMEA - Bathi resik
Pambiji fundamental:Biomea Fusion, Inc.
Produk sing diprodhuksi Biomea Fusion, Inc.

Biomea Fusion, Inc. (BMEA) is scaling resources to develop oral medications for diabetes and metabolic disorders. The dynamics of the company's total assets reflect the aggregate of property and liabilities calculated reversely via the ROA ratio. Growth in this indicator signals an expanding base for future insurance payments but increases requirements for capital efficiency. The stability of the range confirms a resilient financial foundation as the company prepares for the commercialization of its innovations.

Pesaing wigati

ascendispharma.com (ASND) - Total Aset Perusahaan|Aset Agregat Perusahaan Madrigal Pharmaceuticals, Inc.|Corcept Therapeutics Inc. - Nilai Total Aset Perusahaan|Total Aset Perusahaan RYTM|AKRO (Akero Corp) - Nilai Agregat Aset|Total Aset Perusahaan MTSR (Metsera Inc)|Total Aset Perusahaan moonlaketx.com MLTX|CRNX - Aset Agregat Perusahaan|Nilai Agregat Aset NAMS (NewAmsterdam Pharma Company)|Soleno (SLNO) - Aset Agregat Perusahaan|Gunggung Aset Perusahaan Amicus Corp|ETNB (89bio, Inc.) - Total Aset Perusahaan|Total Aset Perusahaan agios.com|Gunggung Aset Perusahaan GPCR (Structure Therapeutics Inc.)|MDXG (MiMedx Group Inc) - Nilai Agregat Aset|Aset Agregat Perusahaan Rezolute Corp RZLT|LXRX - Gunggung Aset Perusahaan|MBX Biosciences Inc - Total Aset Perusahaan|Aset Perusahaan altimmune.com|AARD (Aardvark Therapeutics) - Gunggung Aset Perusahaan|SGMT: Aset Agregat Bisnis|BIOA (BioAge Labs Inc.) - Total Aset Perusahaan|Total Aset Perusahaan Quince|Total Aset Perusahaan GUTS|Aset Agregat Perusahaan VTVT (vtvtherapeutics.com)|Aset Agregat Perusahaan Agape ATP ATPC|Pluristem Therapeutics (PLUR) - Aset Perusahaan|SYBX - Aset Agregat Perusahaan|LPCN: Aset Agregat Perusahaan|MTNB: Total Aset Perusahaan|SPRB - Gunggung Aset Perusahaan|Aset Agregat Perusahaan Galecto|Carmell Corp. (CTCX) - Gunggung Aset Perusahaan|Aset Agregat Perusahaan Lumos Pharma Corp (LUMO)|Gunggung Aset Perusahaan Organovo Corp ONVO|Total Aset Perusahaan RDUS (Radius Recycling, Inc.)